{"id":42058,"date":"2025-09-23T11:23:21","date_gmt":"2025-09-23T03:23:21","guid":{"rendered":"https:\/\/flcube.com\/?p=42058"},"modified":"2025-09-23T11:23:22","modified_gmt":"2025-09-23T03:23:22","slug":"nanjing-leads-biolabs-secures-fda-ind-for-lbl%e2%80%91047-a-first%e2%80%91in%e2%80%91class-bispecific-fusion-protein","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=42058","title":{"rendered":"Nanjing Leads Biolabs Secures FDA IND for LBL\u2011047, a First\u2011In\u2011Class Bispecific Fusion Protein"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Nanjing Leads Biolabs Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/9887:HKG\">HKG: 9887<\/a>) announced today that the U.S. Food and Drug Administration (FDA) has granted Investigational New Drug (IND) approval for its self\u2011developed bispecific fusion protein <strong>LBL\u2011047<\/strong>. The approval allows the company to advance LBL\u2011047 into clinical trials in the United States.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-what-is-lbl-047\">What Is LBL\u2011047?<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dual Targeting Design<\/strong> \u2013 LBL\u2011047 fuses a humanized anti\u2011BDCA2 antibody with a modified extracellular domain of <strong>TACI (transmembrane activator and calcium\u2011modulating ligand interactor)<\/strong>.<\/li>\n\n\n\n<li><strong>Mechanism of Action<\/strong> \u2013 By simultaneously engaging <strong>BDCA2<\/strong> on plasmacytoid dendritic cells (pDCs) and <strong>BAFF\/APRIL<\/strong> pathways via TACI, the molecule suppresses interferon\u2011\u03b1 (IFN\u2011I) secretion and blocks B\u2011cell and plasma\u2011cell differentiation.<\/li>\n\n\n\n<li><strong>Enhanced ADCC<\/strong> \u2013 Glycosylation modifications boost antibody\u2011dependent cell\u2011mediated cytotoxicity, potentially increasing therapeutic potency.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-therapeutic-potential\">Therapeutic Potential<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">LBL\u2011047\u2019s unique dual blockade offers broad suppression of aberrant immune responses, positioning it as a promising candidate for a spectrum of autoimmune disorders in which B cells and\/or pDCs are central drivers. Early pre\u2011clinical data suggest activity in:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Systemic lupus erythematosus<\/li>\n\n\n\n<li>Dermatomyositis<\/li>\n\n\n\n<li>IgA nephropathy<\/li>\n\n\n\n<li>Sj\u00f6gren\u2019s syndrome<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">No other agent has simultaneously targeted BDCA2 and TACI with an IND\u2011approved platform, giving LBL\u2011047 first\u2011in\u2011class advantage.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-and-regulatory-outlook\">Market and Regulatory Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Regulatory Pathway<\/strong> \u2013 The FDA IND clearance paves the way for Phase\u202fI safety studies, with potential rapid progression to Phase\u202fII efficacy trials if early results are favorable.<\/li>\n\n\n\n<li><strong>Commercial Opportunity<\/strong> \u2013 Successful clinical development could unlock a sizable market across multiple autoimmune indications, potentially positioning Nanjing Leads Biolabs as a key player in next\u2011generation immunotherapies.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced today that the U.S. Food and Drug&#8230;<\/p>\n","protected":false},"author":1,"featured_media":42060,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[65,62,4242,1974],"class_list":["post-42058","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-auto-immune","tag-clinical-trial-approval-initiation","tag-hkg-9887","tag-leads-biolabs"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Nanjing Leads Biolabs Secures FDA IND for LBL\u2011047, a First\u2011In\u2011Class Bispecific Fusion Protein - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced today that the U.S. Food and Drug Administration (FDA) has granted Investigational New Drug (IND) approval for its self\u2011developed bispecific fusion protein LBL\u2011047. The approval allows the company to advance LBL\u2011047 into clinical trials in the United States.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=42058\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanjing Leads Biolabs Secures FDA IND for LBL\u2011047, a First\u2011In\u2011Class Bispecific Fusion Protein\" \/>\n<meta property=\"og:description\" content=\"Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced today that the U.S. Food and Drug Administration (FDA) has granted Investigational New Drug (IND) approval for its self\u2011developed bispecific fusion protein LBL\u2011047. The approval allows the company to advance LBL\u2011047 into clinical trials in the United States.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=42058\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-23T03:23:21+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-23T03:23:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2301.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42058#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42058\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Nanjing Leads Biolabs Secures FDA IND for LBL\u2011047, a First\u2011In\u2011Class Bispecific Fusion Protein\",\"datePublished\":\"2025-09-23T03:23:21+00:00\",\"dateModified\":\"2025-09-23T03:23:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42058\"},\"wordCount\":272,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42058#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2301.webp\",\"keywords\":[\"Auto-immune\",\"Clinical trial approval \\\/ initiation\",\"HKG: 9887\",\"Leads Biolabs\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=42058#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42058\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=42058\",\"name\":\"Nanjing Leads Biolabs Secures FDA IND for LBL\u2011047, a First\u2011In\u2011Class Bispecific Fusion Protein - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42058#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42058#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2301.webp\",\"datePublished\":\"2025-09-23T03:23:21+00:00\",\"dateModified\":\"2025-09-23T03:23:22+00:00\",\"description\":\"Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced today that the U.S. Food and Drug Administration (FDA) has granted Investigational New Drug (IND) approval for its self\u2011developed bispecific fusion protein LBL\u2011047. The approval allows the company to advance LBL\u2011047 into clinical trials in the United States.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42058#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=42058\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42058#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2301.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2301.webp\",\"width\":1080,\"height\":608,\"caption\":\"Nanjing Leads Biolabs Secures FDA IND for LBL\u2011047, a First\u2011In\u2011Class Bispecific Fusion Protein\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42058#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanjing Leads Biolabs Secures FDA IND for LBL\u2011047, a First\u2011In\u2011Class Bispecific Fusion Protein\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Nanjing Leads Biolabs Secures FDA IND for LBL\u2011047, a First\u2011In\u2011Class Bispecific Fusion Protein - Insight, China&#039;s Pharmaceutical Industry","description":"Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced today that the U.S. Food and Drug Administration (FDA) has granted Investigational New Drug (IND) approval for its self\u2011developed bispecific fusion protein LBL\u2011047. The approval allows the company to advance LBL\u2011047 into clinical trials in the United States.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=42058","og_locale":"en_US","og_type":"article","og_title":"Nanjing Leads Biolabs Secures FDA IND for LBL\u2011047, a First\u2011In\u2011Class Bispecific Fusion Protein","og_description":"Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced today that the U.S. Food and Drug Administration (FDA) has granted Investigational New Drug (IND) approval for its self\u2011developed bispecific fusion protein LBL\u2011047. The approval allows the company to advance LBL\u2011047 into clinical trials in the United States.","og_url":"https:\/\/flcube.com\/?p=42058","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-23T03:23:21+00:00","article_modified_time":"2025-09-23T03:23:22+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2301.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=42058#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=42058"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Nanjing Leads Biolabs Secures FDA IND for LBL\u2011047, a First\u2011In\u2011Class Bispecific Fusion Protein","datePublished":"2025-09-23T03:23:21+00:00","dateModified":"2025-09-23T03:23:22+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=42058"},"wordCount":272,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=42058#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2301.webp","keywords":["Auto-immune","Clinical trial approval \/ initiation","HKG: 9887","Leads Biolabs"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=42058#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=42058","url":"https:\/\/flcube.com\/?p=42058","name":"Nanjing Leads Biolabs Secures FDA IND for LBL\u2011047, a First\u2011In\u2011Class Bispecific Fusion Protein - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=42058#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=42058#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2301.webp","datePublished":"2025-09-23T03:23:21+00:00","dateModified":"2025-09-23T03:23:22+00:00","description":"Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced today that the U.S. Food and Drug Administration (FDA) has granted Investigational New Drug (IND) approval for its self\u2011developed bispecific fusion protein LBL\u2011047. The approval allows the company to advance LBL\u2011047 into clinical trials in the United States.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=42058#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=42058"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=42058#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2301.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2301.webp","width":1080,"height":608,"caption":"Nanjing Leads Biolabs Secures FDA IND for LBL\u2011047, a First\u2011In\u2011Class Bispecific Fusion Protein"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=42058#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Nanjing Leads Biolabs Secures FDA IND for LBL\u2011047, a First\u2011In\u2011Class Bispecific Fusion Protein"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2301.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42058","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=42058"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42058\/revisions"}],"predecessor-version":[{"id":42061,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42058\/revisions\/42061"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/42060"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=42058"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=42058"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=42058"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}